Real-time enrollment status for this exocrine pancreatic insufficiency (epi) clinical trial
Current Status
Recruiting
Checked: October 13, 2026 at 9:04 AM UTC
| NCT Number | NCT07450547 |
| Recruiting Status | Recruiting |
| Condition | Exocrine Pancreatic Insufficiency (EPI) |
| Phase | PHASE2 |
| Target Enrollment | 113 participants |
| Active Locations | 27 sites in the US |
| Sponsor | Anagram Therapeutics, Inc. |
| Last Updated on CT.gov | October 6, 2026 (1 week ago) |
As of October 13, 2026: Clinical trial NCT07450547 is currently recruiting participants. This phase2 study for exocrine pancreatic insufficiency (epi) is actively seeking new participants at 27 locations across the United States. The study is sponsored by Anagram Therapeutics, Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07450547 is actively recruiting participants as of October 13, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 27 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07450547 was last updated 1 week ago (October 6, 2026). HelloStudys verifies this status automatically.